Professor Jürgen Götz: Ageing dementia and therapeutic ultrasound

The Götz laboratory, which forms part of the Clem Jones Centre for Ageing Dementia Research (CJCADR), aims to understand disease initiation and progression at a molecular and cellular level using cellular and animal models, and to develop novel therapies. We are applying the tools we are developing to also understand fundamental mechanisms of memory or the physiological role of proteins implicated in disease. In recent years, a major focus for the group is in developing therapeutic ultrasound into a treatment modality for human disease.

Find out more


 

Researcher biography

Professor Jürgen Götz (PhD, Dr. habil, FAHMS, GAICD) is Foundation Chair of Dementia Research, Director of the Clem Jones Centre for Ageing Dementia Research at the Queensland Brain Institute (University of Queensland), NHMRC Leadership Fellow and Ultrasound Team Leader. He performed undergraduate studies at the Biocenter of the University of Basel, before joining the laboratory of Nobel Laureate Georges Köhler to obtain his PhD degree in immunology. Subsequently, he took up postdoctoral positions at UCSF (San Francisco) and Sandoz Ltd (now Novartis, Basel), and worked as Research Group Leader (venia legendi, Dr. habil.) at the University of Zurich (Switzerland). Before taking up his current position, Götz was a Professor and Chair of Molecular Biology at the University of Sydney. Götz is an expert in basic research in Alzheimer's disease (AD), focusing on the cellular and molecular mechanisms of how tau and Aβ cause neurodegeneration, using transgenic and cellular models (>210 publications, including in leading journals such as Science, Cell and Neuron (h-index 83, 25,000+ citations, Google Scholar). More recently, Götz developed a non-pharmacological ultrasound-based treatment strategy that removes toxic Aβ and tau in mice and restores memory functions, presenting ultrasound as a novel treatment modality for diseases of the brain. As part of these activites, a clinical-trial ready device has been built and human ethics approval obtained to conduct a first-in-human safety trial in 12 Alzheimer patients. (April 2022)